From:	onbehalfof+muriel.cuendet+unige.ch@manuscriptcentral.com on behalf of 
Pharmaceutical Biology 
[onbehalfof+muriel.cuendet+unige.ch@manuscriptcentral.com]
Sent:	Sunday, November 13, 2016 4:33 PM
To:	rankovic@kg.ac.rs
Subject:	Pharmaceutical Biology - Invitation to Review Manuscript ID NPHB-2016-
2555

13-Nov-2016

Dear Professor Branislav Rankovic:

The above manuscript, entitled "THE ANTICANCER ACTIVITY OF CETRARIA ISLANDICA 
(L.) ACH IN BREAST CANCER CELLS THROUGH CROSSTALK OF AMPK-?1 AND ERK1/2 
SIGNALING" with Dr Ta?k?n as contact author has been submitted to 
Pharmaceutical Biology.

I would be grateful if you would kindly agree to act as a reviewer for this 
paper.  The abstract appears at the end of this letter, along with the names 
of the authors.

Please let me know as soon as possible if you will be able to accept my 
invitation to review.  To do this please either click the appropriate link 
below to automatically register your reply with our online manuscript 
submission and review system, or e-mail me with your reply.

Agreed: 
https://mc.manuscriptcentral.com/nphb?URL_MASK=5440f13c68e04ee093b5ed027392cf7
7

Declined: 
https://mc.manuscriptcentral.com/nphb?URL_MASK=3d5ee5ed4d43495bb171242887964d7
e

Unavailable: 
https://mc.manuscriptcentral.com/nphb?URL_MASK=71fe7616a2284e94b7aa99e6fec527b
5

Should you accept my invitation to review this manuscript, you will be 
notified via e-mail about how to access ScholarOne Manuscripts, our online 
manuscript submission and review system.  You will then have access to the 
manuscript and reviewer instructions in your Reviewer Center.

I realise that our expert reviewers greatly contribute to the high standards 
of the Journal, and I thank you for your present and/or future participation.

Sincerely,

Muriel Cuendet, Ph.D.
Associate Editor
Pharmaceutical Biology


MANUSCRIPT DETAILS

TITLE: THE ANTICANCER ACTIVITY OF CETRARIA ISLANDICA (L.) ACH IN BREAST CANCER 
CELLS THROUGH CROSSTALK OF AMPK-?1 AND ERK1/2 SIGNALING

AUTHORS: Guven, Celal; Yumrutas, Onder; Turker Sener, Leyla; Ozay, Yusuf; Dal, 
Fulya; Ahbab, Mufide; bozgeyik, Ibrahim; Albeniz, Isil; Bagis, Haydar; Yildiz, 
Atilla; Ta?k?n, Eylem

ABSTRACT: Background: In the present study, we aimed to evaluate the 
anticancer activities of ethanol extracts of Cetraria islandica (C.islandica) 
on MCF-7 breast cancer cell lines. Methods: Cell viability was measured by 
using MTT and xCELLigence system. Proteins levels evaluated by a using Western 
Blot. Apoptotic cells were counted by FACS, F-actin distribution was evaluated 
by immunofluorescence dying. Results: In MTT assay, cell viability of MCF-7 
breast cancer cells was found to be reduced in a dose-dependent manner. EC50 
values of C. islandica on MCF-7 cells were found to be 9.2047 E-5 g/ml (cell 
amount) by using xCELLigence system.  Expressions of p53, caspase 3 and Bcl-2 
were shown to be elevated after low doses of extract and diminished after high 
dose treatments. PPAR-? protein level was decreased, although AMP-activated 
kinases-?1 (AMPK-?1) protein level was increased at its extract groups. ERK1/2 
protein level was also elevated at its extract groups. 125 mg/ml of extract 
treated cells show a low decrease in actin filament density. MCF-7 cells with 
C.islandica treatment for 24 h increased the apoptotic cell percentage, though 
the cells-treated with C.islandica for 48 was high necrotic cells percentage. 
Conclusion: The C.islandica extract treatment causes to elevate ERK1/2 and 
AMPK-?1 protein levels, resulting in PPAR-? and then triggers the apoptosis by 
modulation caspase-3 and P53 protein levels. Therefore, C.islandica might be a 
good candidate for anticancer tissue, especially soft tissue tumors.



Agreeing to review an article for this Journal implies that you as the 
reviewer will adhere to the accepted ethical standards of scientific, medical 
and academic publishing. Material submitted for peer review is a privileged 
communication that should be treated in confidence. Material under review 
should not be shared or discussed with anyone outside the designated review 
process, unless approved by the editor. All communications relating to the 
paper in review should also be treated in confidence. Any breach of 
confidentiality in the review process is taken seriously by the journal and 
will be investigated according to the advice of COPE 
(http://publicationethics.org).  Any conflict of interest, suspicion of 
duplicate publication, fabrication of data, plagiarism or other ethical 
concerns must immediately be reported to the Editor.
By agreeing to review this manuscript, you are stating that you are the person 
completing this review.  If you wish to collaborate with a colleague and/or 
trainee to perform this review, or wish to assign this review to a trainee for 
completion under your guidance, please contact the Editor for permission 
before sharing the manuscript.  If the Editor agrees please provide the name, 
affiliation and e-mail address for the trainee/ colleague so he or she may be 
assigned as a reviewer directly.
If you have any conflict of interest (for example, collaborate with the 
author(s) or are currently working on a similar study), please decline to 
review this manuscript and, if possible, suggest appropriate alternate 
reviewers.

Visit www.informahealthcare.com and sign up for free eTOC alerts to all 
Informa Healthcare journals
